Omitting radiotherapy for women with low-risk luminal A breast cancer would produce significant cost savings without adversely affecting outcomes.
This issue of Journal of Clinical Pathways aims to improve how health-related quality of life should be assessed and its impact on patient outcomes.
Companion Diagnostics and Complementary Diagnostics in Clinical Practice: Better Medicine or Competitive Disadvantage?
Authors weigh the benefits and shortcomings of companion diagnostics.
Richard G Stefanacci and his coauthors describe how clinical pathways can be designed to achieve the Triple Aim of care.
Transparency of the evidence synthesis and clinical pathway development processes will be key to ensuring buy-in among stakeholders.
The authors explore how incorporating the role of patient navigators into AD clinical pathways can result in improved outcomes for patients.
Authors explored how price can influence the perception of a product’s clinical effectiveness and positioning for use.
hether value is being defined by the health care provider, the payer, the patient, or industry, the importance of evidence-based treatment decisions and care practices is acknowledged by all stakeholders. The articles in this issue highlight different definitions of value, but they also demonstrate how often these definitions overlap.
The authors discuss how physicians should approach clinical scenarios when the best treatment option lies outside what is recommended on a clinical pathway.
The articles in this issue of Journal of Clinical Pathways aim to shed light on the issues identified by ASCO as being important to ensuring the future success of clinical pathways in oncology.